China CRO Company,Preclinical research services

encnjpkr

News

Our Events

Location:Home > News Center > Our Events > 2016 Recombinant Pro...

2016 Recombinant Protein and Antibody Drug R&D Seminar

Author:   Datetime:2016-11-01  Hits:

    China Pharmaceutical University and Hefei Chaohu Economic Development Zone successfully co-hosted the “2016 Recombinant Protein and Antibody Drug R&D Seminar” at Shenye Holiday Inn Hot Spring Resort recently.  Medicilon congratulated the successful hosting of the seminar and sincerely thanked all the colleagues and peers from the pharmaceutical industry who attended this seminar for their sharing. As one of the co-organizers, Medicilon received a lot of attentions!


    During the seminar, the organizers invited a number of well-known experts and scholars to conduct in-depth discussion and communication with participants on various topics such as MAb and ADC pharmacokinetics and the latest research progress and prospect of Biologics, through presentations and panel discussions.  It played a significant role in promoting the Development of pharmaceutical industry.


Photos From the Seminar and Panel Discussion


Guozhen Xu, VP of Sinobioway Bioeconomy Group Co., LTD. hosted the opening ceremony



Dr. Min Wang, President of China Pharmaceutical University, delivered the welcoming speech



Dr. Ji Li, Vice Chairman of Pharmaceutical Society of Jiangsu Province, delivered a welcoming speech



Dr. Yuexi Li, Vice Chairman of Biochemistry and Molecular Biology Society of Jiangsu Province, delivered a welcoming speech



Wenbo Cao, CEO of Sinobioway Bioeconomy Group, delivered a welcoming speech



Professor Min Wang from China Pharmaceutical University hosted the academic symposium



Huiping Chen from CFDA Audit Center reported for the analysis of common problems in biological products inspection



Dr. Xingchu Gu, VP of Medicilon’s Preclinical Research, reported on preclinical safety evaluation of therapeutic monoclonal antibody



Zongmin Wang, Director of Jiangsu Province Food and Drug Administration Registry, explained on the Reform Policy of Drug Examination and Approval



Dr. Chunlin Chen, CEO of Medicilon, hosted the panel discussion



Professor Yu Liu (Left) and Professor Hanmei Xu (Right) from China Pharmaceutical University hosted the panel discussion



Professor Zichun Hua from Nanjing University reported on long-term effects of protein drugs



Professor Chunmin Rao from National Institute of Food and Drug Control reported on recombinant and antibody drug quality control research



Professor Min Wang from China Pharmaceutical University reported on development of monoclonal antibody in China



Dr. Xiangyang Zhu, General Manager of Huabo Biopharm, reported on the progress antibody drugs research



Dr. Wenzhi Tian from ImmuneOnco shared the experience on antibody drug R & D



Dr. Juan Zhang, Vice Professor of China Pharmaceutical University, reported on the research of anti-tumor angiogenesis antibody JZB01

Prev:Medicilon Tumor Animal Model Debut "SAPA-DC 2017 Annual Scientific Seminar"

Next:Medicilon's Biotechnology Analysis Service Platform